Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma

Liver tumour immune microenvironment subtypes and neutrophil heterogeneity

(2022) Ruidong Xue et al.   NATURE

Immunomodulatory effects of lenvatinib plus anti‐PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma

(2021) Laura Torrens et al.   HEPATOLOGY

Multiplex digital spatial profiling of proteins and RNA in fixed tissue

(2020) Christopher R. Merritt et al.   NATURE BIOTECHNOLOGY

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cytotoxic CD8+ T cells in cancer and cancer immunotherapy

(2020) Hans Raskov et al.   BRITISH JOURNAL OF CANCER

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity

(2020) Won Suk Lee et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

(2019) Jérôme Galon et al.   NATURE REVIEWS DRUG DISCOVERY

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors

(2019) Denarda Dangaj et al.   CANCER CELL

A global view of hepatocellular carcinoma: trends, risk, prevention and management

(2019) Ju Dong Yang et al.   Nature Reviews Gastroenterology & Hepatology

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET